story of the week
Switch to Fulvestrant and Palbociclib vs No Switch in Advanced Breast Cancer With Rising ESR1 Mutations During Aromatase Inhibitor and Palbociclib Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol 2022 Sep 29;[EPub Ahead of Print], FC Bidard, AC Hardy-Bessard, F Dalenc, T Bachelot, JY Pierga, T de la Motte Rouge, R Sabatier, C Dubot, JS Frenel, JM Ferrero, S Ladoire, C Levy, MA Mouret-Reynier, A Lortholary, J Grenier, C Chakiba, L Stefani, JE Plaza, F Clatot, L Teixeira, V D'Hondt, H Vegas, O Derbel, C Garnier-Tixidre, JL Canon, B Pistilli, F André, L Arnould, A Pradines, I Bièche, C Callens, J Lemonnier, F Berger, S DelalogeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.